Table 1_Longitudinal study of factors associated with the anti-cancer efficacy and liver function in HCC patients treated with TACE in combination with percutaneous ablation.docx

BackgroundHepatocellular carcinoma (HCC) is a major cancer challenge worldwide. Combination therapy using transcatheter arterial chemoembolization (TACE) and percutaneous ablation offers potential for improved outcomes.
ObjectiveTo evaluate the efficacy and liver function preservation in HCC patients treated with combined TACE and percutaneous ablation, identifying key prognostic factors.
MethodsThis longitudinal study included 200 HCC patients. Factors analyzed included tumor characteristics, liver function tests, and serologic markers. Statistical analyses determined associations with treatment outcomes and survival.
ResultsSmaller tumors (≤5.0 cm) and lower AFP levels (<200 ng/mL) were associated with higher treatment efficacy, with an objective response rate of 67.3% for lower AFP levels versus 42.3% for higher levels. Liver function was better preserved in patients with lower AFP levels (78.2% vs. 57.7%). Tumor size and liver stiffness significantly influenced survival and liver function outcomes.
ConclusionThe combination of TACE and percutaneous ablation enhances outcomes in HCC, guided by specific prognostic markers. This supports the need for personalized approaches in HCC treatment and further research into combination therapies.

背景：肝细胞癌（hepatocellular carcinoma, HCC）是全球范围内亟待解决的主要癌症挑战。采用经导管动脉化疗栓塞术（transcatheter arterial chemoembolization, TACE）联合经皮消融术的联合治疗方案，具备改善患者预后的潜力。
研究目的：评估肝细胞癌患者接受TACE联合经皮消融治疗的疗效与肝功能保留情况，并明确关键预后因素。
研究方法：本纵向研究共纳入200例肝细胞癌患者，分析指标涵盖肿瘤特征、肝功能检测项目及血清学标志物，通过统计学分析明确其与治疗疗效及生存结局的关联。
研究结果：肿瘤直径≤5.0 cm、甲胎蛋白（alpha-fetoprotein, AFP）水平<200 ng/mL的患者治疗疗效更优；AFP水平较低的患者客观缓解率达67.3%，而AFP水平较高的患者仅为42.3%。AFP水平较低的患者肝功能保留情况更佳（78.2% vs. 57.7%）。肿瘤直径与肝脏硬度显著影响患者生存及肝功能结局。
研究结论：TACE联合经皮消融术可改善肝细胞癌患者的治疗结局，可通过特定预后标志物指导临床治疗。该研究结果支持肝细胞癌治疗需采取个体化方案，并为联合治疗的进一步研究提供了依据。